Effects of Coronary Vasodilators on the Coronary Circulation in the Sclerotic Heart Disease

DOI Web Site Web Site PubMed Open Access
  • ITO Yoshio
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo
  • KOJIMA Yuji
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo
  • HASEGAWA Yoshiyasu
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo
  • SASAMOTO Shugo
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo
  • KISHII Toshiaki
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo
  • KOBAYASHI Tachio
    Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo

Search this article

Description

The effects of 4 coronary vasodilators, i.e. N-[3'-phenyl-propyl-(2')]-1, 1-diphenyl-propyl-(3)-amin (Segontin), 2.6-bis (diaethanolamino)-4, 8-dipiperidino-pyrimido-(5, 4-d) pyrimidin (Persantin), Papaverine hydrochloride and 7-chlorethyitheophylline (ETE) were studied on 19 cases of coronary sclerotic patients by the method of coronary sinus cathetherization.<br>Segontin, Persantin and ETE increased the coronary blood flow, although Papaverine hydrochloride decreased it. Among 4 drugs, only Persantin decreased the coronary vascular resistance, although the tested drugs except ETE decreased or had the tendency to decrease the coronary-systemic resistance ratio, i.e. the relative coronary resistance. At the same time, the oxygen unbalance in the myocardium was slightly improved by Persantin, unchanged after Segontin and Papaverine hydrochloride and became worse after theophylline derivative.<br>The changes of coronary blood flow by these drugs were brought about in part by the changes of mean diastolic pressure or mean diastolic pressure×heart rate, however some other direct or indirect effects of these drugs on the coronary vasculature may be present. Some discussions concerning these points are presented.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top